Clinical trials: Diabetes Mellitus II
Diabetic Neuropathy Peripheral
Evaluation and Treatment for Diabetic Peripheral Neuropathy
This study aims: To compare conventional diabetic neuropathy screening techniques with user-friendly technological equipment; To evaluate the effects of the combined application of laser and therapeutic ultrasound in the…
- Trial name
- NCT07317284
- Testing
- Active Comparator
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo
Diabetes Mellitus
Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin
The purpose of this study is to measure microcirculation in type 2 diabetes patients with peripheral edema who are taking pioglitazone, once daily (QD).
- Trial name
- NCT00676260
- Testing
- Pioglitazone
- Where
- United Kingdom
- Volunteers
- 29 people
- Sponsor
- Takeda
Diabetes, Type I, Diabetes, Type II
Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD
Coronary vascular dysfunction is highly prevalent among patients with known or suspected Coronary Artery Disease (CAD)1, increases the severity of inducible myocardial ischemia (beyond the effects of upstream coronary…
- Conditions
- Diabetes, Type I, Diabetes, Type II, Angina, Coronary Artery Disease
- Trial name
- RAND-CFR (NCT01754259)
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Brigham and Women's Hospital
Diabetes Mellitus
Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.
The purpose of this study is to determine the effect of pioglitazone, once daily (QD), and glimepiride combination therapy compared to glimepiride monotherapy in subjects with Type 2 Diabetes.
- Trial name
- NCT00770952
- Testing
- Pioglitazone and Glimepiride, Glimepiride
- Where
- 17 sites in Germany
- Volunteers
- 91 people
- Sponsor
- Takeda
Type II Diabetes Mellitus, Gestational Diabetes Mellitus
Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids
This study will determine whether rotating intravenous (IV) fluid is better than receiving insulin to control a baby's blood sugar after delivery in laboring women with diabetes.
- Trial name
- NCT03912363
- Testing
- Rotating fluids protocol, Insulin infusion protocol
- Where
- 2 sites in United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Geisinger Clinic
Diabetes Mellitus
Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the combination of alogliptin, once daily (QD), and pioglitazone in patients with type 2 diabetes mellitus who are inadequately controlled with diet and exercise alone.
- Trial name
- NCT00395512
- Testing
- Alogliptin, Pioglitazone
- Where
- 161 sites in United States, Argentina and 21 more
- Volunteers
- 655 people
- Sponsor
- Takeda
Diabetic Foot Ulcer
Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers
This is a phase II/III seamless design, randomized, double-blind, paralleled-group, placebo-controlled study to evaluate the efficacy and safety of Xianglei Tangzu Gao for the treatment of Wagner grade II diabetic foot ulcers.
- Trial name
- NCT06531512
- Testing
- Xianglei Tangzu Gao, Vehicle Cream
- Where
- 14 sites in China
- Volunteers
- 120 people
- Sponsor
- Oneness Biotech Co., Ltd.
Type 2 Diabetes
Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety and to determine the appropriate dose for phase 3 confirmatory trial, of MP-513 (Teneligliptin) in patients with type 2 Diabetes based on the change of HbA1c and…
- Trial name
- NCT00628212
- Testing
- Teneligliptin 10mg, Teneligliptin 20 mg, Teneligliptin 40 mg
- Where
- Japan
- Volunteers
- 324 people
- Sponsor
- Tanabe Pharma Corporation
T2DM (Type 2 Diabetes Mellitus), Low-level Laser Therapy
Effect of Low-level Laser Therapy on Type II Controlled Diabetic Patients After Dental Implant Insertion
This study aimed therefore to evaluate bone density (BD) and OPG levels in the peri-implant crevicular fluid (PICF) in lased controlled type II Diabetes Mellitus (T2DM) patients versus non-lased T2DM patients.
- Conditions
- T2DM (Type 2 Diabetes Mellitus), Low-level Laser Therapy, Bone Density Increased
- Trial name
- NCT05279911
- Testing
- low-level laser therapy (LLLT)
- Where
- 5 sites in Egypt
- Volunteers
- 40 people
- Sponsor
- Sinai University
Diabetic Nephropathy
Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of MT-3995 in Subjects with Diabetic Nephropathy
- Trial name
- NCT01889277
- Testing
- MT-3995-Low, MT-3995-High
- Where
- Japan
- Volunteers
- 51 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus, Type 2, Postmenopausal Symptoms
High Intensity Interval Training in Pre and Postmenopausal Women With Type II Diabetes.
Diabetes Mellitus (DM), a chronic metabolic disease-causing chronic hyperglycemia. Globally more than 90% cases are of type II diabetes mellitus (T2DM).
- Trial name
- NCT07258316
- Testing
- High Intensity Interval Training (warm up, Mat exercises,cycling,HIIT exercises,cool down), Control (warm up, Mat exercises,cycling,Resistance exercises,cool down)
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Riphah International University
Diabete Mellitus
Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3
The purpose of the second phase of the Hypertension Treatment in Nigeria (HTN 2.0) Program is to build upon the success of the first phase of the HTN Program (2020-2023), which implemented the WHO HEARTS package across 60 primary…
- Trial name
- HTN2 (NCT07589387)
- Testing
- Implementation of program based on WHO HEARTS-D guidelines, Metformin, Glimepiride
- Where
- 10 sites in Nigeria
- Volunteers
- 2,800 people
- Sponsor
- Washington University School of Medicine
Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of JNJ-28431754 compared with placebo in patients with type 2 diabetes.
- Trial name
- NCT00642278
- Testing
- Canagliflozin (JNJ-28431754), Sitagliptin
- Where
- 78 sites in United States, Argentina and 11 more
- Volunteers
- 451 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Gastroparesis
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
GSK962040 is a novel small molecule motilin agonist. The Phase I studies (MOT107043 and MOT109681) demonstrated that single doses of GSK962040 up to 150 mg and repeat dosing of up to 125 mg/day for 14 days were well tolerated…
- Trial name
- NCT01262898
- Testing
- GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet)
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Prediabetes
Mitochondrial-related Platelet Transcript Expression Levels in Pre-diabetic Subjects Randomized to Metformin or Placebo
Diabetes mellitus (DM) imposes an approximate 2-fold increased risk of atherothrombosis. Patients with type 2 DM have a 2- to 4-fold increase in the risk of coronary artery disease (CAD) and atherothrombotic complications.
- Trial name
- MAP-2 (NCT02682121)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Utah
Diabetes Mellitus, Type II
Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy
2 weeks screening period, 4 weeks run-in period, 24 weeks double-blind treatment period, to evaluate the Safety and Efficacy of Retagliptin Plus Henagliflozein added to Metformin compared to Retagliptin or Henagliflozein in…
- Trial name
- NCT04667143
- Testing
- Retagliptin, Henagliflozein, metformin XR
- Volunteers
- 760 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes Mellitus Self Management Education, Diabetes Mellitus, Type II
Evaluation of the Effect of Nurse Coaching Program on Self-management and Skin Care Behaviors in Patients With Diabetes
This research will be conducted in a pre-test-post-test randomized controlled, single-blind experimental design to evaluate the effects of a nurse coaching program on self-management and skin care behaviors in patients with…
- Conditions
- Diabetes Mellitus Self Management Education, Diabetes Mellitus, Type II, Skin Care
- Trial name
- NCT06717256
- Testing
- training
- Volunteers
- 42 people
- Sponsor
- Necmettin Erbakan University
Diabetes Mellitus, Non-Insulin-Dependent
Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)
A clinical study determines the safety and efficacy of sitagliptin (MK0431) in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy
- Trial name
- NCT00758069
- Testing
- sitagliptin phosphate, Comparator: Sitagliptin
- Volunteers
- 80 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes
A Phase I/II Trial to Preserve Residual Insulin Secretion in Children With Recent Onset Type 1 Diabetes by Giving Verapamil
The objective of this trial is first to evaluate safety and then the effect on preservation of residual beta cell function also clinical efficacy by treatment with Verapamil in children with recent onset Type 1 diabetes.
- Trial name
- VERADIAB-1 (NCT07199946)
- Testing
- Verapamil (Part A)
- Where
- 2 sites in Sweden
- Volunteers
- 36 people
- Sponsor
- Johnny Ludvigsson
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 1
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic subjects following cataract surgery.
- Trial name
- NCT01853072
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac vehicle, Prednisolone acetate
- Volunteers
- 881 people
- Sponsor
- Alcon Research